TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01686698

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VSL#3 (Original De Simone formulation)
Description: VSL#3 (Original De Simone formulation) is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus, bifidobacteria and lactobacilli.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
Study: NCT05105828

Intervention type: DIAGNOSTIC_TEST
Intervention: Share wave fibro scan
Description: Shear wave elastography (SWE) measures LS by quantifying the velocity of shear waves produced in the liver tissue and uses a normal B-mode ultrasound probe for measuring LS in real time. In addition, SWE imaging using the Aixplorer system provides a high frame-rate and may be able to provide more accurate scoring of fibrosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Share wave fibro scan
Description: Shear wave elastography (SWE) measures LS by quantifying the velocity of shear waves produced in the liver tissue and uses a normal B-mode ultrasound probe for measuring LS in real time. In addition, SWE imaging using the Aixplorer system provides a high frame-rate and may be able to provide more accurate scoring of fibrosis
Study: NCT01464801

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Tablet Resveratrol 500 mg 3 times daily for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet Placebo 3 times daily for 6 months
Study: NCT03141983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: Anakinra (Kineret®) is a therapeutic agent that blocks the effects of IL-1α and IL-1β by competitively binding to the interleukin-1 type I receptor (IL-1RI). It is a recombinant, non-glycosylated form of the naturally occurring human interleukin-1 receptor antagonist (IL-1Ra) but differs from human IL-1Ra in that it has the addition of a single methionine residue at the amino terminus. It is supplied commercially in single use 1 ml prefilled glass syringes as a sterile, clear, colorless-to-white, preservative free solution. Each syringe contains: 0.67 ml (100 mg) of anakinra in a solution (pH 6.5) containing sodium citrate (1.29 mg), sodium chloride (5.48 mg), disodium EDTA (0.12 mg) and polysorbate 80 (0.70 mg) in Water for Injection, USP.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline (0.9%) will be used as the placebo, in single use 1 ml prefilled glass syringes as a sterile, clear, colorless-to-white, preservative free solution.
Study: NCT02134353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled mannitol
Description: Inhaled mannitol 400 mg BD for 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Arm B - Control
Description: Placebo Comparator: Arm B - Control BD for 26 weeks
Study: NCT00322127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100
Description: a 2 mL clear glass vial containing 1.7 mL of a sterile isotonic solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100
Description: a 2 mL clear glass vial containing 1.7 mL of a sterile isotonic solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100
Description: a 2 mL clear glass vial containing 1.7 mL of a sterile isotonic solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100
Description: a 2 mL clear glass vial containing 1.7 mL of a sterile isotonic solution.
Study: NCT02062996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline
Study: NCT01889121

Intervention type: BEHAVIORAL
Intervention: Structured psychosocial intervention
Description: This is retrospective analysis of two groups of opiate-addicted pregnant women: 1) Pregnant women in methadone maintenance program 2) Pregnant women in methadone maintenance program AND structured psychosocial intervention
Study: NCT00805077

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mechanical ventilation
Description: mechanical ventilation with low tidal volume (5 ml/kg of ideal body weight) plus PEEP

Intervention type: OTHER
Group type: OTHER
Intervention: tidal volume
Description: tidal volume of 10 ml/kg of ideal body weight without PEEP
Study: NCT02107287

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT Technique
Study: NCT01629823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure device (Resmed, Swift, Mirage)
Description: Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks and again after a 2-week washout period, 14 weeks after randomization.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure device (Resmed, Swift, Mirage)
Description: Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks and again after a 2-week washout period, 14 weeks after randomization.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Continuous Positive Airway Pressure device (Resmed, Swift, Mirage)
Description: Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks and again after a 2-week washout period, 14 weeks after randomization.
Study: NCT00676572

Intervention type: OTHER
Intervention: Fiberoptic bronchoscopy; blood test
Description: Fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies for histology and culture of airway smooth muscle cells

Intervention type: OTHER
Intervention: Fiberoptic bronchoscopy; blood test
Description: Fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies for histology and culture of airway smooth muscle cells
Study: NCT02608255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples
Study: NCT04053985

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TAI combine lenvatinib
Description: TAI combine lenvatinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: lenvatinib only
Study: NCT00669552

Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention
Description: PCI previously electively scheduled.
Study: NCT02317770

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Spray
Description: 5 puffs of 10% Lidocaine spray is administered every 5 minutes for 4 times. Then the patient is undergone procedure 5 minutes later.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Lidocaine
Description: The patient receives 2.5 mL of 10% lidocaine is used by nebulizer under oxygen flow 6-7 LPM for 15 minutes prior the procedure.
Study: NCT01928797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac output monitor data
Description: The availability of cardiac output monitor provides additional hemodynamic indices that may help guide anesthesiologists to better select vasopressors
Study: NCT00259285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m2, intravenous (IV), every 21 days x 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2, intravenous (IV), every 21 days x 3 cycles
Study: NCT04533243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5ug/h transdermal fentanyl
Description: 2.5ug/h transdermal fentanyl administers for opioid-naive patients with moderate cancer pain very 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral immediate-released morphine
Description: 5mg immediate-released morphine every 4 hours, double dose before sleep.
Study: NCT01474421

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo once daily orally for 28 days.
Study: NCT01880944

Intervention type: OTHER
Intervention: NC-MRI, CE-MRI
Description: non-contrast spine MRI(NC-MRI) contrast-enhanced spine MRI(CE-MRI)
Study: NCT01489462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Strength Training
Description: The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants in this group are lifting 3 sets of each exercise at 75-90% of 1RM.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Intensity Strength Training
Description: The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants are lifting 3 sets of 15 repetitions at 30-40% of 1RM.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Participants in the control group will attend 60-min organized workshops 2 times/month for the first 6 months and then 1 time/month for months 7-18. Over the 18 months interactive presentations will cover such topics as foot care, nutrition, managing medication, and sleep practices, and experts will give wide-ranging lectures.
Study: NCT00006099

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody hu3S193
Description: Hu3S193 was to be administered intraperitoneally or intravenously at a dose of 5mg. Doses of hu3S193 were radiolabeled with 5 mCi of 111In.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody hu3S193
Description: Hu3S193 was to be administered intraperitoneally or intravenously at a dose of 5mg. Doses of hu3S193 were radiolabeled with 5 mCi of 111In.
Study: NCT03466229

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Androferti

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03922295

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic tympanoplasty
Description: In the double flap group, graft is placed via elevation of both posterior and anterior flaps.~In the single flap group, graft is placed via elevation of posterior flap only

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic tympanoplasty
Description: In the double flap group, graft is placed via elevation of both posterior and anterior flaps.~In the single flap group, graft is placed via elevation of posterior flap only
Study: NCT03582150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Monitoring with Ambulatory Detox
Description: * Each Subject willing to participate will sign an Informed Consent and will receive a Subject Number.~* Study staff will assist Subject in setting up the Soberlink Device as well as the Bluetooth enabled blood pressure cuff and Smartphone APP.~* Study staff documents Subject's resting and standing blood pressure and pulse to establish a safety range for the study.~* Subjects will use the blood pressure cuff and the Soberlink Device four times a day per a set schedule to determine blood pressure and pulse and blood alcohol concentration (BAC). Results will be sent to the Soberlink System for study staff to review.~* If the Subject misses a Soberlink test, tests positive for alcohol, or the identity cannot be approved, the staff will be immediately notified by the Soberlink System.~* The Subject will be enrolled on a Monday and evaluated by the study physician and return to the site for an evaluation by the study physician and staff on Tuesday, and a final assessment on Thursday.
Study: NCT03185585

Intervention type: OTHER
Intervention: Mini Nutrition Assessment (MNA® )
Description: MNA® is a validated nutrition screening and assessment tool that can identify geriatric patients age 65 and above who are malnourished or at risk of malnutrition.

Intervention type: OTHER
Intervention: Comprehensive Older Adult Screening Tool (COAST)
Description: Develop a comprehensive older adults screening tool for community dwelling older adults who attend congregate meal sites to assist in the evaluation of undernourishment or those at risk that is simple, faster, and less expensive
Study: NCT01172899

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic adjustable gastric band
Description: Laparoscopic gastric band placement. Combined lifestyle interventions will continue after surgery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined life style interventions
Description: Control group will receive standard therapy consisting of combined lifestyle interventions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined life style interventions
Description: Control group will receive standard therapy consisting of combined lifestyle interventions.
Study: NCT01355471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47 Gel
Description: applied topically once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: applied topically once daily
Study: NCT03705988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cranial Electrotherapy Stimulation(CES)
Description: Cranial electrotherapy stimulation (CES) has been known as a kind of noninvasive treatment, which applies pulsed, weak electrical current to head through two electrodes that placed on the earlobes. The current intensity could be adjusted continuously from 500 μA\~2mA.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham Cranial Electrotherapy Stimulation( sham CES)
Description: Cranial electrotherapy stimulation (CES) has been known as a kind of noninvasive treatment, which applies pulsed, weak electrical current to head through two electrodes that placed on the earlobes. The sham CES devices were identical to the active device, except the ear clip electrodes emit electricity intensity of lower than 100 μA.
Study: NCT02345707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir 30 mg current formulation
Description: Cabotegravir 30 mg current formulation (Treatment A) is a film coated tablet with a weight of 824 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir 30 mg current formulation
Description: Cabotegravir 30 mg current formulation (Treatment A) is a film coated tablet with a weight of 824 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir 30 mg micronized new formulation 500 M
Description: Cabotegravir 30 mg micronized new formulation 500 M (Treatment B) is a film coated tablet with a weight of 515 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir 30 mg unmicronized new formulation 500 U
Description: Cabotegravir 30 mg unmicronized new formulation 500 U (Treatment C) is a film coated tablet with a weight of 515 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir 30 mg micronized new formulation 650 M
Description: Cabotegravir 30 mg micronized new formulation 650 M (Treatment D) is a film coated tablet with a weight of 670 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir 30 mg unmicronized new formulation 650 U
Description: Cabotegravir 30 mg unmicronized new formulation 650 U (Treatment E) is a film coated tablet with a weight of 670 mg
Study: NCT01911936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM716
Study: NCT03505918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No referral for rehabilitation
Description: Intervention is that some patients will not be refered for postoperative physiotherapy.
Study: NCT04130581

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: TMS is a safe and non-invasive technique, which involves the generation of brief magnetic pulses applied to the head through a coil. The magnetic pulses pass through the scalp and skull and induce weak electric currents in the neural tissue directly underneath the coil. When TMS is applied in repetitive, patterned trains of pulses (rTMS), it can induce cortical plasticity specifically in the targeted brain region.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: TMS is a safe and non-invasive technique, which involves the generation of brief magnetic pulses applied to the head through a coil. The magnetic pulses pass through the scalp and skull and induce weak electric currents in the neural tissue directly underneath the coil. When TMS is applied in repetitive, patterned trains of pulses (rTMS), it can induce cortical plasticity specifically in the targeted brain region.
Study: NCT03905213

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dressing MEPORE
Description: assignation to three different authorised and on label dressing: conventional dressing (MEPORE)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dressing MEPILEX
Description: assignation to three different authorised and on label dressing: absorbent(MEPILEX)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dressing PICCO
Description: assignation to three different authorised and on label dressing:vacuum Therapy dressing(PICCO)
Study: NCT02703402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise protocol
Description: Control group will complete all the protocol of exercises with orientation and attendance directly from a professional of physical education, in the Service of Physiatry and Rehabilitation in HCPA.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual of exercises
Description: Treatment group will complete one session of the protocol of exercises with orientation and attendance directly from a professional of Physical Education, in the service of Physiatry and Rehabilitation of HCPA, to clarify any doubts about the protocol. The further sessions will be completed at home, along weekly monitoring of the researchers through phone calls, the patients of this group will receive a manual with the sequence of the exercises
Study: NCT02611921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine will be compounded into a mucosal atomization device and self-administered or administered with assistance of a caregiver/study coordinator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine will be compounded into a mucosal atomization device and self-administered or administered with assistance of a caregiver/study coordinator
Study: NCT04814316

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and urine specimens
Description: Blood and urine samples will be taken at baseline and at the end of the second month. For this purpose, 5 ml of blood samples will be taken to plain blood tubes for evaluation of calcium, magnesium, alkaline phosphatase, parathormone, 25-OH vitamin D and osteocalcin quantities. And 3 ml of urine for calcium, creatinine, deoxypyridinoline, C-terminal telopeptides type-1 collagen and N- terminal telopeptides type-1 collagen.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and urine specimens
Description: Blood and urine samples will be taken at baseline and at the end of the second month. For this purpose, 5 ml of blood samples will be taken to plain blood tubes for evaluation of calcium, magnesium, alkaline phosphatase, parathormone, 25-OH vitamin D and osteocalcin quantities. And 3 ml of urine for calcium, creatinine, deoxypyridinoline, C-terminal telopeptides type-1 collagen and N- terminal telopeptides type-1 collagen.
Study: NCT03910530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Part 1: INCMGA00012 500 mg every 4 weeks administered intravenously over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB001158
Description: Part 1: INCB001158 75 or 100 mg twice daily administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB001158
Description: Part 1: INCB001158 75 or 100 mg twice daily administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab + INCB001158
Description: Part 2: INCB001158 at the recommended Phase 2 dose selected from Part 1 in combination with INCMGA00012 .
Study: NCT01537016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROMOGRAN
Description: PROMOGRAN® is a protease modulating dressing, formulated as a bioresorbable amorphous open-pored matrix constructed of 45% oxidised regenerated cellulose (ORC) and 55% bovine collagen

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROMOGRAN
Description: PROMOGRAN® is a protease modulating dressing, formulated as a bioresorbable amorphous open-pored matrix constructed of 45% oxidised regenerated cellulose (ORC) and 55% bovine collagen

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tielle
Description: Tielle is a hydropolymer foam dressing that is designed to provide optimal wound healing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tielle
Description: Tielle is a hydropolymer foam dressing that is designed to provide optimal wound healing
Study: NCT01917344

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Study: NCT04040634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive Control of Systolic Blood Pressure (SBP)
Description: Participants in the Intensive arm have a goal of SBP \<120 mm Hg. The use of angiotensin converting enzyme (ACE) inhibitors/angiotension receptor blockers (ARB), thiazide-type diuretics, and calcium channel blockers (CCB) will be encouraged, preferably fixed-dose combinations of indapamide + perindopril arginine, perindopril arginine + amlodipine or indapamide + perindopril arginine + amlodipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard control of Systolic Blood Pressure (SBP)
Description: The same medications used in the Intensive BP arm will be used for the Standard BP arm.
Study: NCT03141775

Intervention type: OTHER
Intervention: Treatment of CDI
Description: Treatment (e.g. antibiotics, fecal microbiota transfer (FMT), probiotics) for patients with Clostridium difficile associated diarrhea
Study: NCT04445506

Intervention type: DRUG
Intervention: Dexamethasone
Description: 4mg dexamethasone was given to some patients three times daily for 2 days, 2 times daily for 2 days, once daily for 2 days.